Kevin Dunleavy
Reporter at FiercePharma
Recovering sportswriter, now a reporter for @FiercePharma
Articles
-
1 week ago |
fiercepharma.com | Kevin Dunleavy
Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2.2 billion in sales last year, argenx has scored FDA approval for a new formulation of the treatment, which gives patients the option of administering it at home.
-
2 weeks ago |
fiercepharma.com | Kevin Dunleavy
Merck has handed out another hefty raise to CEO Rob Davis, boosting his compensation by 13% to $23.2 million in 2024, according to the company’s 2025 proxy statement. Since taking the reins from former helmsman Ken Frazier, Davis has seen his pay scale up quickly, from $13.7 million in 2021 to $18.6 million in 2022 and $20.3 million in 2023.
-
2 weeks ago |
fiercepharma.com | Kevin Dunleavy
Over the last few years, with fears increased in the healthcare industry that its top executives could be targets of violence—a concern which was tragically validated in December of last year by the shooting death of UnitedHealthcare CEO Brian Thompson—several pharma companies have been beefing up security protocols for their CEOs.As U.S. drugmakers have released their proxy statements in recent weeks, several reported six-figure expenditures to protect their top execs.
-
2 weeks ago |
fiercepharma.com | Kevin Dunleavy
A New York City federal court has dismissed a proposed class action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market exclusivity of key multiple myeloma drug Pomalyst.
-
2 weeks ago |
fiercepharma.com | Kevin Dunleavy
After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing. The pay package, which is a 4% increase from her compensation the previous year, is particularly significant as Kewalramani is the lone female in an elite peer group: chief executives of biopharma companies that have a market cap of at least $100 billion.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 398
- Tweets
- 3K
- DMs Open
- No
RT @46brooklyndata: Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check @KDunleavy https://t.co/no…
RT @FiercePharma: Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Mye…
RT @FiercePharma: Haleon reels in $633M with sale of ex-US nicotine replacement unit to Dr. Reddy's https://t.co/V1RQCd1fD8